Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...
ANN ARBOR, Mich.--(BUSINESS WIRE)--Following the release of the U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA)/Declaration on Emergency Use of Covid-19 Convalescent Plasma on ...
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. As the proportion of patients infected with COVID-19 continues to rise in the United States, the ...
One potential treatment for COVID-19, known as convalescent plasma, may be derived from patients who have already recovered from the disease, and the US Food and Drug Administration (FDA) said Tuesday ...
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results